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ABSTRACT 
 
Gene-regulatory enhancers have been identified by many complementary lines of 
evidence, including evolutionary conservation, regulatory protein binding, chromatin 
modifications, and DNA sequence motifs. To integrate these different approaches, we 
developed EnhancerFinder, a novel method for predicting developmental enhancers and 
their tissue specificity. EnhancerFinder uses a two-step multiple-kernel learning approach 
to integrate DNA sequence motifs, evolutionary patterns, and thousands of diverse 
functional genomics datasets from a variety of cell types and developmental stages. We 
trained EnhancerFinder on hundreds of experimentally verified human developmental 
enhancers from the VISTA Enhancer Browser—in contrast to histone mark or sequence-
based enhancer definitions commonly used. We comprehensively evaluated 
EnhancerFinder, and we found that our integrative approach improves enhancer 
prediction accuracy over previous approaches that consider a single type of data, such as 
evolutionary conservation and the binding of enhancer-associated proteins. Our tissue-
specific prediction evaluation underscores the importance of considering enhancers of 
different tissues, in addition to non-enhancer regions, when attempting to learn specific 
types of enhancers. We find that VISTA enhancers active in embryonic heart are easier to 
predict than enhancers active in several other embryonic tissues due to their uniquely 
high GC content. We applied EnhancerFinder to the entire human genome and predicted 
84,301 developmental enhancers and their tissue specificity. These predictions provide 
specific functional annotations for large amounts of human non-coding DNA, and are 
significantly enriched near genes with annotated roles in their predicted tissues and hits 
from genome-wide association studies. We demonstrate the utility of our enhancer 
predictions by identifying and validating a novel cranial nerve enhancer in the ZEB2 
locus. Our genome-wide developmental enhancer predictions are freely available as a 
UCSC Genome Browser track.  
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AUTHOR SUMMARY 
 
The human genome contains an immense amount of non-coding DNA with unknown 
function. Some of this DNA is responsible for regulating exactly when and where genes 
are turned on during development. Enhancers, which are a type of regulatory element, are 
short stretches of DNA that can act as “switches” to turn a gene on or off at specific times 
in specific cells or tissues. Understanding where in the genome enhancers sit can provide 
insight into development, genetic diseases, and even response to drug treatment. 
Enhancers are hard to find, but clues to their locations are found in different types of data 
including DNA sequence, certain proteins’ binding to the DNA, and the evolutionary 
history of that stretch of DNA. We introduce a new method, called EnhancerFinder, that 
combines thousands of newly available datasets to predict the location and activity of 
enhancers. EnhancerFinder was trained on the largest set of known human enhancers 
available, and we find that it works very well. We use EnhancerFinder to predict tens of 
thousands of enhancers in the human genome. These predictions will be useful in 
understanding functional regions hidden in the vast amounts of non-coding DNA.
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INTRODUCTION 
 
Eukaryotic gene expression is regulated by a highly orchestrated network of events, 
including the binding of regulatory proteins to DNA, chemical modifications to DNA and 
nucleosomes, recruitment of the transcriptional machinery, splicing, and post-
transcriptional modifications. Enhancers are genomic regions that influence the timing, 
amplitude, and tissue specificity of gene expression through the binding of transcription 
factors and co-factors that increase transcription (as reviewed in [1,2]). In humans, 
genetic variation in enhancer regions is implicated in a wide variety of developmental 
disorders, diseases, and adverse responses to treatments [3,4].  
Enhancers have been discovered in introns, exons, intergenic regions megabases 
away from their target genes [5], and even on different chromosomes [6]. An enhancer 
frequently drives only one of many domains of a gene’s expression [7,8] and different 
cell types accordingly exhibit considerable differences in their active enhancers [9,10]. 
This modularity enables the creation of complex regulatory programs that can evolve 
relatively easily between closely related species [11,12].  
Individual enhancers were initially identified using transgenic assays in cultured cell 
lines [13,14] and later in vivo in model organisms, such as mouse, Drosophila, and 
zebrafish. In the in vivo experiments, a construct containing the sequence to be tested for 
enhancer activity, a minimal promoter, and a reporter gene (e.g., lacZ) is injected into 
fertilized eggs, and transgenic individuals are assayed for reporter gene expression. 
Studies of this type typically investigate regulation of a single locus, as has been done for 
Bmp5, Shh, and RET [15,16,17], because transgenic assays are too low throughput for 
genome-wide analyses.  
Early efforts to find enhancers at the genome scale used comparative genomics. 
Several studies assayed non-coding regions conserved across diverse species for enhancer 
activity [18,19,20], since functional non-coding regions likely evolve under negative 
selection. This approach identified many enhancers at a range of levels of evolutionary 
conservation [21,22,23]. However, relying on evolutionary conservation alone has 
several shortcomings: many characterized enhancers are not conserved between species 
[24], non-coding conservation is not specific to enhancer elements, and evolutionary 
patterns provide little information about the tissue and timing of enhancer activity.  
Enhancer prediction has been revolutionized by recent technological advances, 
including chromatin immunoprecipitation coupled with high-throughput sequencing 
(ChIP-seq) [25], RNA sequencing (RNA-seq), and sequencing of DNaseI-digested 
chromatin (DNase-seq) [26] or formaldehyde-assisted isolation of regulatory elements 
(FAIRE-seq) [27]. These “functional genomics” assays enable genome-wide 
measurement of histone modifications, binding sites of regulatory proteins, transcription 
levels, and the structural conformation of DNA. The ENCODE project [28] and similar 
studies focused on specific developmental cell types [29,30] have dramatically increased 
the amount of publicly available functional genomics data.  
Functional genomics studies revealed several genomic signatures of active enhancers. 
For example, known enhancers are associated with the unstable histone variants H3.3 and 
H2A.Z [31,32] and low nucleosome occupancy [33], although these chromatin states are 
not unique to enhancers. Monomethylation of lysine 4 on histone H3 (H3K4me1), a lack 
of trimethylation at the same site (H3K4me3), and acetylation of lysine 27 on histone H3 
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(H3K27ac) may distinguish active enhancers from promoters [9,34,35], enhancers that 
are “poised” for activity later in development [36,37], and regulatory elements that 
repress gene expression [38,39]. Additional features that pinpoint specific classes of 
active enhancers include binding of the transcriptional cofactor p300/CBP [20,40,41,42], 
clusters of transcription factor (TF) binding sites [43,44,45,46], and enhancer RNA 
transcription (eRNAs)[47]. Collectively, functional genomics data have pinpointed the 
locations of many novel enhancers and yielded insights into sequence and structural 
determinants of enhancer activity. However, these patterns have not proven to be 
universal [48,49], and there is unlikely to be a single chromatin signature that identifies 
all classes of enhancers [10,50,51]. 
Given the complexity of these functional genomics data sets, computational methods 
have been developed to improve and generalize the enhancer predictions made from 
simple combinations of these data. Support vector machines (SVMs) and linear 
regression models trained to interpret DNA sequence motifs underlying known enhancers 
have successfully identified novel enhancers active in heart [52], hindbrain [53], and 
muscle [54] development. Another approach used SVMs to learn patterns of short DNA 
sequence motifs that distinguish markers of potential enhancers, such as p300 and 
H3K4me1, in different cellular contexts [55,56]. Random forests have been used to 
predict p300 binding sites from histone modifications in human embryonic stem cells and 
lung fibroblasts [57]. Machine-learning algorithms have also been applied to the related 
problem of selecting functional TF binding sites out of the thousands of hits to a TF’s 
binding motif throughout the genome [58,59,60,61,62,63,64]. Finally, two groups have 
taken a less supervised approach and used hidden Markov models (ChromHMM) [65] 
and dynamic Bayesian networks (Segway) [66] to segment the human genome into 
regions with unique signatures in ENCODE data and to assign potential functions, such 
as enhancer activity, to these states. 
While rich datasets coupled with sophisticated algorithms have successfully identified 
many novel enhancers, comprehensive enhancer prediction is challenging for three main 
reasons. First, no single type of data is currently sufficient to identify all enhancers active 
in a given context. Many of the approaches described above use a single mark or motif as 
a proxy for an enhancer, but this gives an incomplete representation of all biologically 
active enhancers. Second, while a great deal of functional genomics data is available for 
different cell lines and tissues, it is not understood how informative experiments in a 
given cellular context are about enhancer activity in other contexts. Finally, many 
different approaches have been taken to find enhancers using functional genomics data 
and/or sequence features, and the relative merits of each technique are not well 
understood. 
With these issues in mind, we introduce a new two-step machine-learning method for 
predicting enhancers and their tissue specificity. In machine learning, a classification 
algorithm is trained to distinguish between labeled training examples (e.g., enhancers and 
non-enhancers) based on features of these labeled examples (e.g., evolutionary 
conservation, chromatin signature, DNA sequence). The trained classifier can then be 
used to predict the labels for uncharacterized genomic regions (e.g., which ones are 
enhancers). Our approach employs two rounds of a supervised machine-learning 
technique called multiple kernel learning (MKL) [67,68]. MKL is based on the theory of 
SVMs [69], but provides greater flexibility to combine diverse data (e.g., evolutionary 
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conservation, sequence motifs, and functional genomics data from different cellular 
contexts) and to interpret their relative contributions to the resulting predictions. In our 
two-step MKL algorithm, which we call EnhancerFinder, we first train a classifier to 
distinguish known human developmental enhancers in the VISTA enhancer database [70] 
from the genomic background. In the second step, we train classifiers to distinguish 
among enhancers in VISTA with different tissue specificity. In contrast to most other 
enhancer prediction strategies, which are trained on a epigenetic marks or sequence motif 
that serve as a proxy for a subset of all active enhancers, our use of a heterogeneous and 
in vivo validated set of enhancers, enables us to characterize the complex suite of features 
that underlie active regulatory regions. Our two-step approach allows us to determine 
more accurate signatures of enhancers with activity in specific contexts. 
Our analyses demonstrate that EnhancerFinder’s integration of diverse types of data 
from many different cellular contexts significantly improves prediction of validated 
enhancers over previous approaches. We find that enhancers active in some 
developmental contexts are easier to identify than others. Applying EnhancerFinder to the 
entire human genome, we predict more than 80,000 developmental enhancers, with 
tissue-specific predictions for brain, limb, and heart. These predictions significantly 
overlap known non-coding regulatory regions and are enriched near relevant genome-
wide association study hits and genes expressed in the predicted tissue. To illustrate the 
utility of our enhancer predictions, we use them to investigate the regulation of the ZEB2 
gene and experimentally validate a new cranial nerve enhancer nearby.  
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RESULTS 
 
We present EnhancerFinder, a novel machine learning-based enhancer prediction pipeline 
that allows the seamless integration of feature data from a variety of experimental 
techniques and biological contexts that have previously been used individually to predict 
enhancers (Figure 1). We use MKL to integrate these data. MKL algorithms learn a 
weighted combination of different “kernel” functions that quantify the similarity of 
different feature data in order to make predictions. In EnhancerFinder, we use three 
kernels based on different types of biological feature data: DNA sequence motifs, 
evolutionary conservation patterns, and 2496 functional genomics datasets. 
 EnhancerFinder could be used to predict enhancers active in any life stage and 
tissue. In this study, we evaluate EnhancerFinder’s ability to predict developmental 
enhancers and their tissue specificity. Step 1 of our pipeline aims to distinguish all 
enhancers active in the context of interest (i.e., a specific developmental stage) from non-
enhancer regions. Step 2 then builds classifiers to predict the tissues in which the 
enhancer candidates from Step 1 are active. In contrast to one-step approaches, this two-
step approach allows us to accurately identify enhancers, while also distinguishing their 
tissues of activity.  
We train and evaluate EnhancerFinder using the VISTA Enhancer Browser, which 
contains over 700 human sequences with experimentally validated enhancer activity in at 
least one tissue at embryonic day 11.5 (E11.5) in transgenic mouse embryos. VISTA also 
contains a similar number of regions without enhancer activity in this context. E11.5 in 
mouse development roughly corresponds to E41 (Carnegie stage 17 [71]) in human 
development. In Step 1 of EnhancerFinder, we used all 711 VISTA enhancers as positive 
training data, and for negative training data, we created a set of 711 random regions 
matched to the length and chromosome distribution of the positives to represent the 
genomic background. In Step 2, we considered all enhancers in VISTA with activity in a 
tissue of interest as positives and all other regions in VISTA (including enhancers of 
other tissues and regions not found to be active at E11.5) as negatives (see Methods). 
This second step that includes enhancers active in other tissues in the training proves to 
be essential for obtaining high specificity in predicting tissue of activity. 
To evaluate EnhancerFinder, we compared it to several commonly used enhancer 
prediction approaches. We evaluated the performance of all prediction algorithms using 
10-fold cross validation to compute the area under the curve (AUC) for receiver 
operating characteristic (ROC) curves. We also computed precision-recall curves 
(Supplementary Figure 1) and compared power at a low false positive rate. 
 
EnhancerFinder integrates diverse data types to accurately identify developmental 
enhancers  
EnhancerFinder predicts enhancers by integrating classifiers based on three distinct data 
types: functional genomics data, evolutionary conservation patterns, and DNA sequence 
motifs. Combining these different approaches enables EnhancerFinder to accurately 
distinguish enhancers from the genomic background (Figure 2A; AUC = 0.96).  
The functional genomics component of EnhancerFinder (which we refer to as All 
Functional Genomics) is a linear SVM that incorporates 2469 datasets generated by the 
ENCODE project and smaller scale studies. These include DNaseI hypersensitivity data 
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and ChIP-Seq for p300, many histone modifications, and many TFs from many adult and 
embryonic tissues and cell lines (Supplementary Table 1). DNA sequence patterns are 
integrated via a 4-spectrum kernel (DNA Motifs), which summarizes the occurrence of 
all length four DNA sequences (4-mers) in input regions [72]. We found that little was 
gained by increasing k, considering multiple k simultaneously, or incorporating 
knowledge of transcription factor binding site (TFBS) motifs (Supplementary Figures 2 
and 3). Finally, evolutionary conservation information is incorporated with a linear SVM 
that uses mammalian phastCons scores [73] as features (Evolutionary Conservation). 
 
EnhancerFinder performs significantly better than previous enhancer prediction 
approaches  
Our motivation for developing EnhancerFinder was to explore whether combining 
previous successful approaches to enhancer prediction would improve performance. Each 
of the classifiers combined in EnhancerFinder is representative of a different strategy for 
predicting enhancers. Thus, we compared the performance of EnhancerFinder to each of 
its constituents, which are SVMs trained on the same enhancer data as EnhancerFinder, 
but using only one type of the data features (e.g., only sequence motifs). EnhancerFinder 
significantly outperformed each of the individual classifiers (Figure 2A; p=2.0E-7 for 
Evolutionary Conservation, p=2.6E-8 for DNA Motifs, and p=4.4E-16 for All 
Functional Genomics, McNemar’s test), suggesting that these different types of data 
capture unique aspects of enhancers that are not completely encompassed by any single 
data type. Of the three component classifiers in EnhancerFinder, Evolutionary 
Conservation yields the best performance (AUC=0.93). This reflects the fact that nearly 
all validated enhancers in VISTA are strongly conserved compared to the genomic 
background and many were selected for testing based on their conservation. This is surely 
an over-estimate of the performance of this approach, and we address this issue in more 
detail when describing our tissue-specific and genome-wide predictions below. The DNA 
Motifs (AUC=0.88) and All Functional Genomics (AUC=0.89) classifiers also exhibit 
strong performance, but do not perform as well as the combined classifier. 
EnhancerFinder has nearly twice the power of any of the individual classifiers at a 5% 
false positive rate (FPR), and its power advantage is even larger at lower FPRs.  
All Functional Genomics, DNA Motifs, and Evolutionary Conservation 
achieve roughly similar performance from different feature data, but each individual 
classifier predicts a somewhat different set of enhancers during evaluation (Figure 2B). 
Roughly two-thirds of the enhancer predictions are shared between the three classifiers. 
The improvement provided by combining these data argues that these data sources are 
indeed complementary. 
 We also compared EnhancerFinder’s performance with CLARE, a popular 
method for identifying enhancers from DNA sequence data, i.e., transcription factor 
binding site motifs and other sequence patterns [74]. This approach has been successfully 
applied in several contexts [52,53,54,75] and is publicly available as a web server. On our 
Step 1 enhancer prediction task, we find that CLARE achieves an ROC AUC of 0.79. 
This is much lower than our DNA Motifs method (AUC=0.88) and the full 
EnhancerFinder (AUC=0.96; Figure 2C). At a 5% FPR, the power of CLARE is about 
20%, compared to approximately 30% for DNA Motifs and more than 60% for 
EnhancerFinder. 
 9 
 Finally, we compared EnhancerFinder to ChromHMM and Segway [65,66], two 
unsupervised machine learning methods for segmenting the genome into a small number 
of functional “states” based on consistent patterns in ENCODE data. The states resulting 
from the segmentations were annotated by hand into predicted functional classes, which 
include enhancer activity. It is difficult to directly compare our supervised method to 
these unsupervised approaches, but we believe it is informative, since they are commonly 
used to interpret uncharacterized non-coding regions. To evaluate these methods, we 
considered the states overlapping our training and testing regions. Any region with an 
overlapping enhancer state was considered a predicted enhancer and all others were 
predicted non-enhancers. In this way, we obtained a single point in performance 
evaluation space for the state predictions. Since there is no score or confidence value 
associated the state assignments, a full ROC curve could not be created for these 
methods. Figure 2C gives the performance for several versions of ChromHMM and 
Segway based on ENCODE data from different cell lines. Both methods perform better 
than random, but considerably worse than other approaches (p≈0). We stress that, in 
contrast to our supervised method, these methods were not explicitly trained to perform 
the same task as EnhancerFinder, and instead are attempting to solve a more general 
problem. However, this result argues that their utility in identifying developmental 
enhancers is limited compared to specialized approaches. 
 
Integrating diverse functional genomics data improves enhancer prediction 
As illustrated above, our machine learning prediction and evaluation framework enabled 
us to quantitatively explore the utility of different genomics datasets in enhancer 
prediction by creating classifiers based on types of data (i.e., sequence motifs, 
evolutionary conservation, and functional genomics) and comparing their performance. 
We also used this framework to investigate other questions about the utility of different 
subsets of these data for enhancer prediction. For example, one might expect that some of 
the datasets included in All Functional Genomics (e.g., experiments in cancer cell lines 
or adult tissues) would not be as useful as others (e.g., experiments in embryonic tissues) 
for predicting developmental enhancers, and that limiting the features examined by the 
classifier to the most relevant experiments might improve performance.  
To explore this hypothesis, we trained linear SVM classifiers to predict VISTA 
enhancers (as in Step 1 of EnhancerFinder) based on different subsets of all the functional 
genomics features (Supplementary Table 1) and compared their performance. First, we 
considered a collection of 244 datasets from embryonic tissues and cell lines (Embryonic 
Functional Genomics). Next, we created a classifier that considers data from a wider 
range of contexts by training a linear SVM using a large, manually curated set of 509 
potentially relevant functional genomics data sets (Relevant Functional Genomics). 
This set includes embryonic datasets, along with additional DNaseI and ChIP-Seq data 
from adult tissues and cell lines related to the dominant tissues of activity in VISTA. For 
example, we included data from human cardiac myocytes, since there are many 
developmental heart enhancers in our training examples. We compared these to the All 
Functional Genomics classifier described above that uses all 2496 functional genomics 
features. 
All Functional Genomics (AUC=0.89) performed slightly better than Relevant 
Functional Genomics (AUC=0.87; p=0.16), and both significantly outperformed 
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Embryonic Functional Genomics (AUC=0.83; p=9.2E-9 and p=2.7E-6, respectively) 
(Figure 3A). At low FPRs, the differences in power between these classifiers were 
modest. The Embryonic Functional Genomics classifier included the most time-
appropriate datasets, yet its performance was improved by including additional data sets 
that seem less relevant to our classification problem a priori. Thus, we conclude that it 
can be advantageous to consider a wide range of functional genomics features, many of 
which may not be directly associated with enhancer activity or measured in the context of 
interest. The utility of these additional data sets might indicate that some enhancer 
features are stable across cell types and developmental stages, but it could also reflect 
information these data provide about genomic regions that are not active enhancers 
during development (see Discussion). 
 
Histone marks and p300 provide complementary information about enhancer 
activity 
We also explored the utility of individual functional genomics datasets that are often used 
as proxies for developmental enhancers by creating three linear SVM classifiers: 
H3K27ac, H3K4me1, and p300. These SVMs were trained to distinguish VISTA 
positives from the genomic background (Step 1) using all available data of the specified 
type from ENCODE, which include a range of cell types and tissues (Supplementary 
Table 1). All three classifiers performed better than random (Figure 3B). H3K4me1 
(AUC=0.72) and p300 (AUC=0.68) performed similarly (p=0.25), with p300 performing 
best at low FPRs and H3K4me1 best at higher FPRs. Both significantly outperformed 
H3K27ac (AUC=0.61; p=9.4E-15 and p=5.5E-9, respectively). Since combinations of 
these features are often used to predict enhancers, we next trained a linear SVM classifier 
(Basic Functional Genomics) that includes all three data types together. The combined 
classifier significantly outperforms all the individual classifiers (AUC=0.77; p<2E-7 for 
each), suggesting that each data type contributes unique information about enhancer 
activity. Also, all four SVM classifiers achieved much better performance than the 
common approach of simply considering regions overlapping with these data 
(Supplementary Figure 4).  
EnhancerFinder also learns weights for individual features within classifiers that 
reflect their contribution to the enhancer predictions. We found that features known to be 
associated with enhancer activity in relevant cellular contexts generally receive positive 
weights, while those associated with other types of elements received negative weights 
(Supplementary Text and Supplementary Figure 5). 
 
EnhancerFinder’s two-step approach enables tissue-specific enhancer prediction 
In the previous sections, we focused on generic developmental enhancer prediction (Step 
1 of EnhancerFinder). Step 2 of EnhancerFinder applies a second round of MKL to refine 
and further annotate predicted enhancers from Step 1 (Figure 1). In this study, Step 2 
consists of training an MKL classifier to distinguish VISTA enhancers active in a given 
tissue from VISTA regions without activity in that tissue, i.e., non-enhancers plus 
enhancers for other tissues. We did not require that the positive training examples be 
active only in the tissue of interest. Using the same feature data as in Step 1, we created 
tissue-specific classifiers for all tissues with more than 50 examples in VISTA: forebrain, 
midbrain, hindbrain, heart, limb, and neural tube.  
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The performance of EnhancerFinder’s tissue specificity predictions varied 
dramatically between tissues (Figure 4), with the best performance for heart (AUC=0.85), 
followed by limb (AUC=0.74), forebrain (AUC=0.72), midbrain (AUC=0.72), hindbrain 
(AUC=0.69), and neural tube (AUC=0.62), which was the worst of the tested tissue 
classifiers, but better than random. We combined all brain enhancers into one class, and 
the performance of this generic brain classifier was similar to that of the more specific 
brain classifiers (AUC=0.73). Consistent with our observations from Step 1, the 
EnhancerFinder tissue-specific classifiers trained with all data types achieved the best 
performance for most tissues (Supplementary Table 2). However, classifiers based on 
functional genomics alone often performed almost as well as the full EnhancerFinder 
classifier, suggesting functional genomics data may be more informative about enhancer 
tissue specificity than conservation or sequence motifs. 
Most previous efforts to predict tissue-specific enhancers have performed a single 
training step using enhancers or enhancer marks present in the tissue of interest as 
positives and non-enhancer regions or the genomic background as negatives. To test 
whether our two-step method improves upon these previous approaches, we trained one-
step MKL classifiers and compared their predicted tissue distributions to those of 
validated enhancers from the VISTA database (Figure 5A). First, we trained a set of 
tissue-specific classifiers using enhancers active in a given tissue as positives and the 
genomic background as negatives. These classifiers predict very similar sets of enhancers 
regardless of the target tissue; and they vastly overestimate the number of VISTA 
enhancers that are active in multiple tissues (95% versus 8% of VISTA) and the number 
of true enhancers of each tissue (Figure 5B). In contrast, classifiers trained as in Step 2 of 
EnhancerFinder, i.e., using tissue-specific enhancers as positives and a mix of enhancers 
active in other tissues and regions with no VISTA activity as negatives, show much 
greater tissue-specificity in their predictions (76%) and a similar amount of overlap as in 
the known enhancers (Figure 5C).  
 
Heart enhancers are uniquely easy to identify due to their high GC content 
The relative ease of identifying heart enhancers is due in large part to their having several 
unique characteristics. Known heart enhancers at E11.5 are significantly less 
evolutionarily conserved than enhancers in other tissues [40,42]. In addition, we observed 
that heart enhancers at this developmental stage are uniquely close to the nearest 
transcription start site (TSS) (Supplementary Figure 6). However, the distinct attribute of 
heart enhancers most relevant to enhancer prediction is their unusually high GC content 
(49%). A simple classifier based solely on the GC content of a region performs nearly as 
well as our full classifiers (Supplementary Figure 7). In contrast, enhancers of other 
tissues at E11.5 exhibit much lower GC content (~40%) that is not significantly different 
from the genomic background, and as a result sequence-based classifiers do not perform 
well on the other tissues (Supplementary Table 2). The high GC content of heart 
enhancers is not due to overlap with CpG islands. Only about 4% of VISTA enhancers 
overlap with a CpG island, and this number is consistent across tissues. We do see, 
however, that repeat regions in heart enhancers are depleted for the very AT-rich repeats 
seen in other enhancers, and that most of the repeat regions in heart enhancers are 40-
60% GC.  
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We predict more than 80,000 developmental enhancers across the human genome 
One of the main motivations for developing algorithms that can distinguish active 
enhancers is to apply them to uncharacterized genomic regions to aid the exploration and 
interpretation of the gene regulatory landscape of the human genome (Figure 1). To 
produce a genome-wide set of candidate developmental enhancers, we divided the 
genome into 1.5 kb blocks overlapping one another by 500 bp and applied Step 1 of 
EnhancerFinder to each of these regions. EnhancerFinder produces a score for each 
region; positive scores indicate membership in the positive set (enhancers), and negative 
scores indicate membership in the negative set (non-enhancers). To focus on high 
confidence predictions in this genome-wide analysis, we used the cross-validation-based 
evaluation described above to find a 5% FPR score threshold, and only considered 
regions exceeding this threshold. After merging overlapping positive predictions, we 
identified 84,301 developmental enhancers across the human genome with median length 
of 1,500 bp and total genome coverage of 183,695,500 bp (5.86%). 
The 5% FPR threshold we used corresponds to a 65% true positive rate (TPR). To 
calculate the false discovery rate (FDR), we must estimate the unknown fraction of 1.5 kb 
blocks of the human genome that harbor developmental enhancer regions. If this fraction 
were as high as 50%, a 5% FPR would correspond to a 9% FDR. If instead we estimate 
that 10% of 1.5 kb windows contain a developmental enhancer, we see an FDR of 47% at 
a 5% FPR. While this may seem high, our recent analysis of predicted enhancers with 
human-specific substitution rate acceleration found a much lower false validation rate at 
E11.5 (5/29) [75].  This suggests that these FDR estimates may be pessimistic, especially 
when predicted enhancer regions are analyzed in the context of other relevant data.  
In our genome-wide analysis, we used the smaller Relevant Functional Genomics 
data set in order to reduce the computational time required. We also did not include 
evolutionary conservation data, because the positives in our training data are almost 
universally conserved; 706 of the 711 VISTA enhancers overlap a conserved element. 
While most enhancers likely exhibit some evolutionary conservation, this extremely high 
fraction is likely due to bias in the selection of the tested regions in VISTA and could 
reduce our ability to detect less highly conserved novel enhancers genome-wide (see the 
Discussion). The resulting conservation-free classifier still performed extremely well in 
cross validation (AUC=0.92). Supporting this approach, non-conserved regions make up 
over 20% of our genome-wide enhancer predictions. We did not observe any other 
dramatic biases in the feature data associated with human VISTA enhancers. 
Next, we applied Step 2 of EnhancerFinder to all enhancer regions predicted in Step 
1. We focused on brain, limb, and heart, because these tissues are highly represented in 
VISTA and have been extensively studied in previous analyses of developmental 
enhancers. We predicted 7,400 limb enhancers, 19,051 heart enhancers, and 11,693 brain 
enhancers (Figure 6) at a 5% FPR threshold tuned separately for each tissue. Since 
EnhancerFinder makes predictions for each tissue independently, there are no constraints 
on the distribution of tissues in the resulting genome-wide predictions. Nonetheless, we 
find a high level of tissue-specificity; 77% of the limb, heart, and brain enhancers are 
predicted to be active in just one of the three tissues.  
All genome-wide enhancer predictions are available as tracks for import into the 
UCSC Genome Browser (Supplementary Data Files). These lists of tissue-specific 
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enhancers should not be viewed as exhaustive; we found thousands of regions with 
positive, but less significant scores from Step 2 of EnhancerFinder. 
 
Predicted enhancers are associated with relevant functional genomic regions 
To characterize and further validate our genome-wide enhancer predictions, we examined 
their genomic distribution with respect to several independent indicators of function 
(details in Supplementary Text). Genes near brain and heart enhancers are enriched for 
expression in relevant tissues (Supplementary Tables 3 and 4). Similarly, Gene Ontology 
(GO) Biological Process enrichment analyses of the nearby genes suggest that our 
predicted developmental enhancers target genes that function in relevant cell types and 
tissues (Figure 6). The most prevalent transcription factor binding site motifs found in the 
sequences of predicted enhancers differed between enhancers of different tissues and 
included many relevant developmental TFs (Supplementary Table 5). Finally, our 
predicted enhancers contain 676 single nucleotide polymorphisms (SNPs) associated with 
significant effects in genome-wide association studies (GWASs) (Supplementary Table 
6); this is significantly more overlap than expected at random (permutation p < 0.001). 
Taken together, these analyses suggest that EnhancerFinder identifies many active 
regulatory regions that contain functionally relevant variation. Our tissue-specific 
enhancer predictions give valuable annotations to previously uncharacterized non-coding 
regions of the human genome. For example, thousands of SNPs associated with disease 
by GWASs are in non-coding regions with limited functional annotations [76]. Our 
genome-wide enhancer predictions provide a resource for exploring the mechanisms and 
functional effects of these uncharacterized GWAS hits.  
 
Case Study: EnhancerFinder predictions highlight a novel enhancer near ZEB2 
To illustrate how genome-wide enhancer predictions from EnhancerFinder can be used to 
facilitate the discovery of regulatory elements, we present a case study that identifies and 
validates a novel enhancer region near the human ZEB2 gene, a zinc finger E-box-
binding homeobox-2 TF (Figure 7). We selected the ZEB2 locus for several reasons. 
ZEB2 has many roles throughout embryonic and postnatal development, in particular in 
cortical neurogenesis [77,78,79,80], and mutations in ZEB2 are associated with Mowat-
Wilson syndrome, a complex developmental disorder [81]. However, relatively little is 
known about the genetic mechanisms that orchestrate ZEB2’s expression. A long-range 
enhancer of postnatal expression in developing kidney cells (E1 in Figure 7) was recently 
discovered 1.2 megabases (Mb) downstream of ZEB2 in the adjacent gene desert [82]. 
Since this enhancer does not fully recapitulate the expression timing and domains of 
ZEB2, the authors speculate that the gene has many other, potentially long-range, 
enhancers. Supporting this theory, there are two validated E11.5 brain enhancers near 
ZEB2 in the VISTA database (Figure 7, VISTA 407 and VISTA 1802). Finally, there is 
an enrichment of human accelerated regions (HARs) [83,84] near ZEB2, suggesting that 
it may have human-specific regulatory patterns. 
Our enhancer predictions support the existence of a rich regulatory program specified 
in the non-coding sequence nearby ZEB2; there are 54 predicted enhancers for which it is 
the nearest TSS. This puts ZEB2 in the top 0.2% of all genes with respect to the number 
of adjacent enhancer predictions. Supporting the validity of our predictions, the known 
VISTA enhancers both overlap EnhancerFinder predicted enhancers, while the regions 
 14 
tested by [82]and found to be not active or active at a later post-natal developmental stage 
(only E1) do not.  
We selected the predicted enhancer indicated in the zoomed pane of Figure 7 for 
further experimental analysis due to its high EnhancerFinder score and overlap with a 
HAR. We interrogated the potential of the human and chimp sequences at this region to 
drive gene expression at E11.5 in transient transgenic mouse embryos. All seven embryos 
with staining showed cranial nerve expression (Figure 7 red box; Supplementary Figure 
9), regardless of whether the construct contained the human or chimp sequence. Thus, we 
have identified a novel enhancer for ZEB2. Our enhancer predictions highlight many 
additional candidates for the further investigation of the regulation of ZEB2. We believe 
that our predictions will enable similar analyses of the regulatory landscape near many 
other genes of interest.  
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DISCUSSION 
 
In this study, we developed EnhancerFinder, a new machine-learning framework for 
predicting regulatory enhancers from diverse data sources. In contrast to most previous 
enhancer identification strategies, which have based their predictions on one or a small 
number of data types, EnhancerFinder enables us to flexibly integrate the large and 
continually expanding collection of evolutionary, DNA sequence, and functional 
genomics data that are informative about enhancer function. Our analysis of the 
EnhancerFinder algorithm and its predictions makes three major contributions. First, we 
demonstrate that integrating diverse types of data from many cellular contexts, including 
some unexpected ones, improves prediction performance. Second, we show that enhancer 
tissue-specificity can be accurately predicted through a two-step approach in which 
tissues are individually evaluated after general enhancer prediction. Finally, our genome-
wide developmental enhancer annotations, including tissue-specific predictions for heart, 
brain, and limb, highlight thousands of previously un-annotated genomic regions. We 
show that these predictions are enriched for a number of independent indicators of 
regulatory functions. As a result, we expect our predictions to prove useful in the 
annotation of non-coding genomic regions, as illustrated in the identification of a novel 
cranial nerve enhancer near ZEB2. The genome-wide predictions are freely available as a 
UCSC Genome Browser track.  
 
A biologically active in vivo definition of “enhancer.” We chose to define developmental 
enhancers for training as genomic regions that are experimentally shown to activate gene 
expression in vivo in embryonic mouse assays. This is a narrow definition, but we believe 
it is better suited to defining regions for further exploration and experimental 
characterization than approaches based on single data sources associated with enhancers. 
We show that our predicted enhancers, based on this biologically active definition, 
significantly overlap data sets commonly used as proxies for enhancer activity, such as 
H3K27ac and p300 binding. However, this does not imply that these other data alone are 
sufficient to identify enhancers, as we demonstrated for H3K27ac, H3K4me1, and p300 
in Figure 3B. Similarly, when we evaluate the ability of previous computational methods 
for identifying enhancers, we find that they perform better than random, but significantly 
worse than EnhancerFinder, at identifying biologically active enhancers. 
 While EnhancerFinder can be used to predict enhancers in well-characterized cell 
lines, it is particularly useful at identifying enhancers in complex tissues that contain 
multiple cell types and in cell types that might not have much specific functional 
genomics data available. Other computational approaches to enhancer prediction have 
focused on identifying enhancers in individual cell types using functional genomics data 
from the same cells [57] or going one step further and using the differences in cell type 
specific transcription factor binding to identify cell-type specific binding motifs [62]. 
These methods generally perform well, but they do not address enhancer prediction in 
cell types with little or no functional genomics data, or in tissues that contain multiple 
cell types.  
 
Why do seemingly irrelevant data improve our enhancer predictions? Data such as p300 
binding sites and H3K4me1 have been used in previous studies to identify enhancers, and 
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these data are major contributors to our enhancer predictions. However, data from many 
other sources and contexts less directly associated with enhancer activity provide 
complementary information that improves our predictions. Some of these data may be 
negatively correlated with enhancer activity, allowing EnhancerFinder to learn what 
features distinguish regions that are not developmental enhancers. Others may help 
reinforce patterns present in data from more relevant contexts, reflecting some degree of 
stability in the features of enhancer regions across developmental stages and cell types. 
For example, we found that features measured in embryonic stem cells are quite useful 
for E11.5 enhancer prediction; their removal from the classifier degrades performance 
and/or they have large (positive or negative) MKL weights. Examination of these features 
suggests that some identify “poised” regions that will become active enhancers upon 
differentiation, while others seem to help distinguish stem cell enhancers (i.e., non-
enhancers at E11.5) from those specific to differentiated lineages. We note that despite 
these interesting observations, most individual features do not carry a great deal of 
information and the power of EnhancerFinder comes from the integration of many data 
sets. It is also possible that as a more complete experimental characterization of 
chromatin state and protein-DNA binding from E11.5 tissues is obtained, extra data from 
less relevant contexts will not provide as much improvement as it did in this study.  
 
What data are most informative about enhancer activity? We focused on a single 
developmental stage with a large number of validated enhancers. To efficiently extend 
enhancer detection and validation to new contexts, it will be very important to select the 
most informative data to collect. Even though the ENCODE project has produced an 
impressive amount of data, it still has not extensively assayed most contexts of interest to 
researchers, in particular developmental biologists. The performance of classifiers trained 
on subsets of all our data and the weights we learned for feature sets and individual 
features provide some guidance for future experiments. Evolutionary conservation and 
DNA sequence patterns are broadly useful in the identification of enhancers, but our 
results suggest that adding functional genomics data is necessary to make more precise 
predictions about the contexts of activity. H3K4me1 and p300 are two of the most useful 
functional genomics data types overall (Supplementary Figure 5), but many others are 
useful in particular contexts. 
 
Why are heart enhancers easier to predict than other types of enhancers? We saw a 
broad range in our ability to predict the tissue specificity of enhancers from existing data. 
Heart enhancers were dramatically easier to identify than other tissue-specific enhancers. 
Heart enhancers have significantly higher GC content than enhancers of other tissues, are 
less evolutionarily conserved, and are closer to the nearest TSS than other known 
enhancers at E11.5, and we show that GC content alone is sufficient to accurately predict 
many heart enhancers (Supplementary Figures 6 and 7). The underlying biological 
explanation for these patterns may have to do with relative developmental age of 
different organs and tissues. At E11.5, the heart is further along its developmental 
trajectory than the other tissues considered. At this stage, many of the less conserved, 
mammal-specific features of the heart are developing [85,86], whereas other tissues are 
still developing under more general, less species-specific conserved regulatory programs 
at E11.5 [87]. A recent study of enhancers in the adult mouse retina found that high local 
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GC content was strongly correlated with enhancer activity [88]. Paired with our result, 
this suggests that GC content is a distinguishing feature of certain classes of enhancers.  
 
Limitations of our approach. In spite of the strong overall performance of 
EnhancerFinder at predicting tissue-specific developmental enhancers, our approach has 
some limitations. First, we rely heavily upon the VISTA Enhancer Browser for training 
examples, because it is the largest collection of validated mammalian enhancers currently 
available. This resource provides an impressive catalog of validated human regulatory 
enhancers, but it is limited to a single developmental stage and experimental system. 
Without more data and analysis, it is difficult to evaluate how specific our predictions are 
to this context. Applying EnhancerFinder to known enhancers in model organisms, such 
as zebrafish and fly, would provide additional opportunities to evaluate our approach and 
findings, while potentially demonstrating differences in how enhancers function in these 
different species. 
Second, most of the enhancers present in VISTA are evolutionarily conserved. As 
a result, the VISTA enhancers cannot be viewed as an exhaustive catalog of the full range 
of enhancers. However, these regions have validated enhancer activity in vivo, and thus 
provide an appealing alternative to approaches that use single-mark proxies for enhancer 
activity (e.g., considering all H3K27ac peaks as active enhancer regions). We mitigated 
the impact of the bias towards conserved regions by removing evolutionary conservation 
as a feature from EnhancerFinder when we applied it to predict enhancers genome-wide. 
Our goal in doing so was to improve our ability to discern less conserved enhancers in 
these genome-wide predictions. This enabled the identification of thousands of non-
conserved enhancers (~20% of all predictions).  
Third, though our predictions are based on a large collection of genome-wide 
chromatin state, protein-binding, and sequence information from many contexts, we are 
still limited by data availability. Even with the impressive efforts of ENCODE and 
related projects, producing data that are perfectly matched to all contexts of interest is 
time consuming and sometimes impossible, especially when studying humans. Thus, it 
will be important to develop a principled understanding of how different data can be 
generalized across tissues, developmental stages, and between species. In our analysis, 
the highest weighted features come from contexts close to the developmental stage of 
interest, and thus we anticipate that gathering more data from developmentally relevant 
cells and tissues will significantly improve our ability to annotate genomic regions 
involved in the regulation of embryonic development. However, data from other, 
seemingly unrelated, contexts may continue to prove useful.  
 
Extensions and future applications. This study makes a significant contribution towards 
annotating regulatory elements in the human genome and provides tools for interpreting 
the effects of mutations in non-coding regions. Our case study on the region around ZEB2 
illustrates how our predictions can facilitate the rapid identification of novel enhancers. 
In addition, the statistical enrichment for GWAS SNPs in our genome-wide enhancer 
predictions suggests that they may be a good resource for pinpointing causal mutations in 
potential disease loci. 
EnhancerFinder is a general framework for enhancer prediction and rigorous 
evaluation of different data sources that aim to annotate the regulatory functions of the 
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human genome. It could easily be extended to include additional types of data, such as 
population-level variation at each locus, information about the three-dimensional state of 
the genome from Hi-C and 5C, and predictions of potential target genes for each 
enhancer. It could also be used to analyze additional aspects of the data we already 
consider, such as accounting for the relative genomic position of different features [67].  
The EnhancerFinder two-step approach enables delineation of features common to all 
enhancers versus those that characterize enhancers of different types. For example, we 
find that predicting the tissue specificity of enhancers that are unique to a single tissue is 
more difficult than those that are active in multiple tissues (Supplementary Figure 8), that 
certain features make prediction of heart enhancers particularly easy, and that different 
features are selected in classifiers for general enhancers and those for specific tissues. 
Together, these results suggest that there may be distinct classes of enhancers, even 
amongst those active in a given tissue at a single developmental stage. Further analysis of 
EnhancerFinder classifiers based on different types of data may help suggest biological 
mechanisms underlying the functional distinctions and genomic features of these 
different classes of enhancers.  
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METHODS 
 
All work presented in this paper is based on the February 2009 assembly of the human 
genome (GRCh37/hg19) downloaded from the UCSC Genome Browser 
(http://genome.ucsc.edu/). Any data that was not in reference to this build was mapped 
over using the liftOver tool from the UCSC Kent tools 
(http://hgdownload.cse.ucsc.edu/admin/jksrc.zip). 
 
Multiple kernel learning-based prediction of developmental enhancers 
In our framework, genomic regions are associated with a common set of descriptive 
features. We then apply machine-learning algorithms that use the features of known 
training examples to learn a function of the feature data that distinguishes the positives 
(enhancers) from the negatives (non-enhancers). This function can then be applied to the 
features associated with uncharacterized genomic regions to predict their enhancer status. 
A positive score for a genomic region indicates predicted membership in the positive 
class (enhancers) and a negative score indicates predicted membership in the negative 
class (non-enhancers).  
 
Training examples 
We obtained all of our positive training data and our tissue-specific negative training data 
from the VISTA Enhancer Browser [70] on April 4, 2012. We downloaded the location, 
DNA sequence, and expression contexts for all human sequences tested in the VISTA 
mouse E11.5 enhancer screen. This consisted of 711 validated human enhancers and 736 
genomic regions that did not exhibit enhancer activity in this context 
(http://enhancer.lbl.gov/). The median length of the enhancers in VISTA is 1,545 bp.  
In the first step of EnhancerFinder (Figure 1), we used all 711 VISTA enhancers as 
positive training data. For negative training data, we generated a set of 711 random 
genomic regions matched to the length and chromosome distribution of the positives, and 
filtered to remove known VISTA enhancers and assembly gaps. 
In the second step of EnhancerFinder, we used tissue-specific subsets of the 1,447 
VISTA regions for positive and negative training data. For example, when predicting 
heart enhancers, our positive training data were the 84 VISTA regions with heart 
expression in E11.5 mice, and our negative training data were the remaining 1,363 
VISTA regions that were tested and showed no heart expression at E11.5, even though 
they may be enhancers in other tissues. We did not require that a region be active only in 
the tissue of interest. We included the VISTA negatives in this analysis, because they 
share many attributes in common with known enhancers and may have enhancer activity 
in contexts other than E11.5. Our results did not change dramatically when the VISTA 
negatives were not included in the training. We trained tissue-specific classifiers for the 
six tissues with more than 50 examples in VISTA: forebrain, midbrain, hindbrain, 
heart, limb, and neural tube. We also trained a brain enhancer classifier on the combined 
the forebrain, midbrain, and hindbrain enhancers. 
 
Feature data 
We consider three main types of data as features in our analysis: functional genomics 
data, evolutionary conservation, and DNA sequence motifs. We obtained our functional 
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genomics feature data from the ENCODE data repository at the UCSC Genome Browser 
(http://genome.ucsc.edu/ENCODE/ and [89]). These data include histone modifications, 
such as H3K4me1, H3K4me3, H3K27ac, protein-DNA associations for many TFs and 
p300, and several measurements of open chromatin (DNaseI hypersensitivity, FAIRE, 
digital genomic footprinting), from hundreds of cell types [89]. We also included heart 
p300 data from [40]. For a full list of the functional genomics data considered, see 
Supplementary Table 1. We associated each genomic region with a binary vector that 
represents the presence or absence of overlap with each functional genomics data set. To 
determine this feature vector, we intersected the genomic location of the region of interest 
with the peaks defined by the original researchers (from the broadPeak or narrowPeak 
files) using intersectBed [90]. We found that considering non-binary functional genomics 
features based on experimental data, like the density of sequence reads from a ChIP-seq 
study, did not significantly improve performance (data not shown). However, we suspect 
that with consistent peak calling and appropriate normalization this might be an avenue 
for future improvement. 
To summarize the DNA sequence motif patterns in a genomic region, we calculated 
the number of occurrences of all possible 4-mers in the sequence.  
Evolutionary conservation estimates were taken from the mammalian phastCons 
elements [73] obtained from the phastConsElements46wayPlacental track in UCSC 
Genome Browser. Each genomic region was assigned its maximum overlapping 
phastCons score or zero if it did not overlap any phastCons elements.  
 
Machine-learning algorithms  
EnhancerFinder is an extension of the SVM supervised learning framework that allows 
the integration of multiple data types into a single discrimination function. Standard 1-
norm MKL augments the usual SVM discrimination function, f, with additional 
parameters, βj, that weight the contribution of each kernel function kj: 
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where N is the number of training examples, M is the number of kernels, αi are the 
training example weights, and b is the bias [67]. We include three kernel functions in 
EnhancerFinder, each of which corresponds to one of the three types of feature data 
described above. These kernels quantify the similarity of the features of the appropriate 
type for any two genomic regions. To combine the kernels, the MKL algorithm 
simultaneously learns weights for the associated kernels, in addition to learning the bias 
and weights for each training example as in a standard SVM. We use the 4-spectrum 
kernel [72] for our sequence features; this kernel has been shown to perform well in a 
variety of DNA sequence-based prediction tasks including enhancer prediction [55]. For 
the functional genomics and evolutionary conservation data, we use linear kernels, which 
are equivalent to dot products of the feature vectors. We investigated using more 
sophisticated kernel functions for these features, but Gaussian and polynomial kernels did 
not yield any consistent improvement. Each kernel was variance normalized, and we 
balanced the misclassification costs by class size [91]. In addition to EnhancerFinder 
classifiers, we also trained and evaluated the constituent single kernel SVMs. All 
analyses were performed using the implementation of SVMs and MKL in the SHOGUN 
Machine Learning Toolbox v1.1.0 [92].  
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Performance evaluations 
To evaluate the performance of trained classifiers, we performed 10-fold cross-validation 
on the training data and quantified our results with ROC AUC, precision-recall curves, 
and power estimates at fixed false positive rates. We computed p-values for the 
difference in performance between classification methods using McNemar’s test [93,94]. 
To estimate false discovery rates, we trained EnhancerFinder classifiers at 1:1, 1:10, and 
1:100 ratios of positive to negative enhancers and used the resulting 10-fold cross-
validation results to calculate the proportion of false discoveries genome-wide at a 5% 
FPR if the true proportion of 1.5 kb windows containing an enhancer was 50%, 10%, or 
1%.  
 
Comparison to existing enhancer prediction methods 
We compared EnhancerFinder’s predictions to those of several previous enhancer 
prediction methods. We obtained the performance of CLARE on our Step 1 prediction 
task, by inputting our positive and negative data into the CLARE web server [74]. We 
downloaded the genomic segmentations and annotations produced by ChromHMM [65] 
and Segway [66]. We considered the ChromHMM predictions based on different 
ENCODE cell lines both individually and together. Any genomic region in our evaluation 
data set that overlapped an enhancer state was considered a predicted enhancer, and all 
others were considered predicted non-enhancers. For Segway, we also considered the 
“TF activity” state. 
 
Identification of tissue-specific enhancers across the human genome 
We predicted tissue-specific developmental enhancers throughout the human genome by 
applying a trained MKL classifier (Step 1 of EnhancerFinder) without conservation (see 
Results) to sliding windows of 1500 bp, moving along the human genome in 500 bp 
steps. The feature profile for each window was computed as described above. To focus 
on high-confidence predictions, we filtered the enhancer scores for the windows at a 5% 
FPR, estimated from cross-validation using the genomic background, and combined the 
remaining overlapping windows to produce 84,301 high-confidence predicted enhancers.  
To predict tissue specificity, we applied trained brain, limb, and heart classifiers (Step 
2 of EnhancerFinder) without conservation to all 299,039 windows with positive 
enhancer scores in Step 1. We then applied a 5% FPR cutoff for each tissue and 
concatenated the remaining overlapping windows into merged enhancer regions. Using 
this approach, we predicted 19,051 heart enhancers, 11,693 brain enhancers, and 7,400 
limb enhancers. 
 
Analysis of genome-wide tissue-specific enhancer predictions 
We characterized the expression patterns of the gene nearest to each predicted enhancer 
using the GNF Atlas 2 [95]. It contains expression data for genes in 79 different tissues, 
with expression measured using Affymetrix microarrays. For each of these 79 tissues, we 
used a paired t-test to determine if the nearest genes of predicted heart enhancers had 
significantly different mean values of expression than the nearest genes of brain 
enhancers. We did not include the limb enhancers in this analysis due to the lack of 
relevant expression data in the GNF Atlas 2. 
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We examined genomic regions near predicted developmental enhancers for 
enrichment of Gene Ontology functional annotations, known phenotypes, and pathways 
using GREAT [96]. Results were computed using the hypergeometric test for genome-
wide significance, with the default settings and the “basal plus extension” association rule 
(proximal 5 kb upstream, 1 kb downstream, plus distal up to 100 kb). 
We identified the sequence motifs present in each set of enhancers using the FIMO 
tool (Find Individual Motif Occurrences) from the MEME Suite of sequence motif 
analysis tools [97]. We considered known transcription factor binding motifs from the 
April, 2011 release of the TRANSFAC database with a FIMO score threshold of 10e-5. 
We identified those occurrences that fell in predicted enhancers, and summarized motifs 
to identify the most prevalent TFs in each tissue-specific set of enhancers. 
We analyzed the overlap of predicted enhancers with GWAS SNPs, based on the 
NHGRI catalog of 9,687 GWAS SNPs downloaded from the UCSC Genome Browser in 
October 2012. Unadjusted permutation p-values were calculated by randomizing genomic 
locations of predicted enhancers (matching for length and chromosome, and avoiding 
assembly gaps) and overlapping these randomized regions with GWAS SNPs to assess 
significance of overlapping regions.  
 
Transgenic Enhancer Assays 
Enhancer assays were carried out in transient transgenic mouse embryos generated by 
pronuclear injections of expression constructs into FVB embryos (Cyagen Biosciences). 
Human and chimpanzee DNA sequences were inserted upstream of a minimal promoter 
and a LacZ reporter gene. The human sequence was amplified using primers 5'-
TGTATGAAACCTGTTCACTCTCC-3' and 5'-
GCTTAAAACAACTACTAGAATCAGGC-3' from the bacterial artificial chromosome 
(BAC) RP11-107E5 (from the BacPac resource at CHORI). The chimpanzee sequence 
was amplified using primers 
5'-TGTATGAAACCTGTTCACTCTCC-3' and 5'-
GCTTAAAACAACTACTAGAATCAGGC-3' from BAC CH251-677E03a (CHORI). 
The embryos were collected and stained for LacZ expression at E11.5. 
Following the annotation policies of the VISTA Enhancer Browser, we required that 
consistent spatial expression patterns be present in three or more embryos with staining in 
order for the region to be considered an enhancer. 
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FIGURE CAPTIONS 
 
Figure 1. Overview of the EnhancerFinder enhancer prediction pipeline. In our two-
step approach, regions of the genome are characterized by diverse features, such as their 
evolutionary conservation, regulatory protein binding, chromatin modifications, and 
DNA sequence patterns. For each step, appropriate positive (green) and negative (purple) 
training examples are provided as input to a multiple kernel learning (MKL) algorithm 
that produces a trained classifier (black box). We used 10-fold cross validation to 
evaluate the performance of all classifiers. In Step 1, we trained a classifier to distinguish 
between known developmental enhancers from VISTA and the genomic background. In 
Step 2, we trained several classifiers to distinguish enhancers active in tissues of interest 
from those without activity in the tissue according to VISTA. We applied the trained 
enhancer classifier from Step 1 to the entire human genome to produce more than 80,000 
developmental enhancer predictions. We then applied the tissue-specific enhancer 
classifiers from Step 2 to further refine our predictions. 
 
Figure 2. Combining diverse data using EnhancerFinder improves the identification 
of enhancers. (A) Enhancer prediction strategies based on functional genomics data, 
evolutionary conservation, and DNA sequence motif patterns all perform well, but 
EnhancerFinder, which combines these data, provides significant improvement over each 
of them alone (p<2.0E-7 for all). (B) Each of the approaches from (A) predicts that 
somewhat different sets of the VISTA regions are enhancers. This suggests that 
complementary information is contained in each data source. EnhancerFinder (not 
shown), which combines them, captures many of the enhancers that are unique to each 
source; it predicts 25 of the 44 enhancers unique to Functional Genomics, 30 of the 76 
unique to DNA Sequence Motifs, and 34 of the 111 unique to Evolutionary 
Conservation.  (C) EnhancerFinder also outperforms several other published approaches 
to enhancer prediction. CLARE is a machine learning method based on known regulatory 
motifs. ChromHMM and Segway are unsupervised clustering methods that have been 
used to segment the genome into different functional states based on patterns in 
functional genomics data. The enhancer predictions of ChromHMM and Segway do not 
distinguish VISTA enhancers from the genomic background as well as our machine 
learning approaches. Each “X” gives the performance achieved at the Step 1 enhancer 
classification problem obtained by considering any region that overlaps a ChromHMM 
enhancer state a positive and all others a negative. The different X’s represent state 
predictions based on data from different ENCODE cell types: GM12878 (blue), H1-
hESC (violet), HepG2 (brown), HMEC (tan), HSMM (gray), HUVEC (light green), 
K562 (green), NHEK (orange), NHLF (light blue), and all contexts combined (red). The 
circles give the performance of the Segway “enhancer” and “TF activity” states. 
 
Figure 3. Integrating diverse functional genomics data improves enhancer 
prediction. (A) Considering all functional genomics features, including those from 
contexts and assays not expected to be associated with developmental enhancer activity 
(All Functional Genomics and Relevant Functional Genomics), improves the ability of 
the classifiers to identify developmental enhancers (Embryonic Functional Genomics; 
p=9.2E-9 and p=2.7E-6, respectively). (B) Combining H3K4me1, p300, and H3K27ac 
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data, which are commonly used in isolation to identify enhancers, in a linear SVM (Basic 
Functional Genomics) is better able to distinguish known developmental enhancers from 
the genomic background than considering each type of data alone (p<2E-7, for each). 
However, combining these marks still performs significantly worse than EnhancerFinder 
(Figure 2A; AUC=0.96). 
 
Figure 4. Enhancers of heart expression are easier to identify than enhancers active 
in other tissues at E11.5. (A) We trained EnhancerFinder using the same features as in 
Step 1 (Figure 1), but using VISTA enhancers active in a given tissue as positives and 
tested regions that did not show activity in the tissue as negatives (Step 2). Heart 
enhancers were dramatically easier to identify than enhancers of expression in other 
tissues. The heart enhancers have significantly higher GC content than other enhancers 
and the genomic background, and this largely explains the ease of identifying them 
(Supplementary Figure 7). In general, EnhancerFinder improves on it component 
methods when predicting tissues of activity, but functional genomics data alone often 
perform competitively (Supplementary Table 2). 
 
Figure 5. EnhancerFinder’s two-step approach captures tissue-specific attributes of 
enhancers. (A) The true overlap of human enhancers of brain, heart, and limb in the 
VISTA database. The vast majority of enhancers are unique to one of these tissues at this 
stage. For example, of the 84 validated heart enhancers, 71 are unique to heart, five are 
shared with brain, four with limb, and four with both. (B) The predicted overlap of 
VISTA enhancers based on predictions made with a single training step using MKL with 
only enhancers of that tissue considered positives and the genomic background as 
negatives. This approach overestimates the number of enhancers active in multiple 
tissues. Each classifier mainly learns general attributes of enhancers, rather than tissue-
specific attributes. (C) The predicted overlap based on EnhancerFinder’s two-step 
approach. These predictions are much more tissue-specific and exhibit overlaps between 
tissues similar to the true values (A). Tissue distributions for the classifiers in (B) and (C) 
are similar when they are applied to other genomic regions, as illustrated in our genome-
wide predictions; only predictions overlapping VISTA enhancers are shown here to 
enable comparisons to the distribution for validated enhancers (A). 
 
Figure 6. Predicted tissue-specific enhancers exhibit tissue-specific characteristics. 
EnhancerFinder identifies thousands of novel high-confidence (FPR < 0.05) heart, brain, 
and limb enhancers. These enhancers are enriched for tissue-specific GO Biological 
Processes. The five most enriched GO Biological Processes among genes near each 
enhancer set (as calculated using GREAT) are listed in the colored boxes. Over 70% of 
EnhancerFinder predicted heart, brain, and limb enhancers are unique to a single tissue. 
The larger number of high-confidence heart enhancers relative to brain and limb 
enhancers is the result of the superior performance of the heart classifier. 
 
Figure 7. A novel cranial nerve enhancer in the ZEB2 locus. This screen shot from the 
UCSC Genome Browser shows a dense region of predicted enhancers in a 1.5 Mb 
window on human chromosome 2 including ZEB2 and part of the adjacent gene desert. 
Tracks give the locations of four human accelerated regions (HARs), two validated 
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VISTA enhancers, and the E1 region recently shown to have postnatal enhancer activity 
by [82]. The inset shows a zoomed in view of ZEB2 (hg19.chr2:145,100,000-
145,425,000) along with summaries of several ENCODE functional genomics datasets 
and evolutionary conservation across placental mammals. We tested the predicted 
enhancer overlapping 2xHAR.240 for enhancer activity at E11.5 in transgenic mice. Both 
the human and chimp versions of this sequence drive consistent expression in the cranial 
nerve (Supplementary Figure 9). 
 
 
 
SUPPLEMENTARY FIGURE CAPTIONS 
 
Supplementary Figure 1. Precision-Recall curves corresponding to all ROC curves 
presented in the main text. (A) Figure 2A (B) Figure 2C The CLARE method, which is 
included in main text Figure 2C, was not included in this corresponding figure because 
we could not obtain the raw scores from regions from the web server (C) Figure 3A (D) 
Figure 3B (E) Figure 4. 
 
Supplementary Figure 2. The 4-spectrum kernel performs competitively with other 
k-spectrum kernels and the combination of k-spectrum kernels. We analyzed the 
ability of spectrum kernels based on k-mer lengths between 2 and 8 to distinguish 
enhancers from the genomic background (Step 1). K-mers between 4 and 7 had the best 
performance.  We also evaluated an MKL algorithm that combined each k-spectrum 
kernel, and it did not provide significant improvement over the best individual kernels. 
 
Supplementary Figure 3. Considering known TFBS motifs does not improve the 4-
spectrum kernel. Considering the number of occurrences of known TFBS motifs as 
features has recently been used in a linear SVM framework to predict enhancers [53]. To 
evaluate the utility of this approach, instead of and in addition to considering all k-mers, 
we created a linear SVM that used the number of hits to 1022 TF binding site matrices 
from TRANSFAC and JASPAR as computed by FIMO as features. That is the feature 
vector for each region consisted of 1022 elements, each of which was the number of 
significant hits for a different TF motif. This TFBS linear SVM (AUC=0.81) did not 
perform as well as the 4-spectrum kernel (AUC=0.88). We also evaluated an MKL 
algorithm that combined the 4-spectrum and TFBS kernels. This combined kernel did not 
perform any better than the 4-spectrum kernel suggesting that, at least under this 
encoding, TFBS motifs do not provide significant additional benefit in distinguishing 
enhancers from the genomic background. 
 
Supplementary Figure 4. Combining functional genomics data with an SVM 
outperforms simply considering regions overlapping these data.  The four solid lines 
shown are the same as in Figure 4B; they summarize the performance of these methods at 
distinguishing VISTA enhancers from the genomic background (Step 1). The X’s give 
the performance of an approach that considers all regions overlapping a given feature as 
positives and all others as negatives. The + and * indicate the performance obtained by 
considering the union and intersection of H3K4me1, p300, and H3K27ac, respectively. 
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For each feature, the linear SVM achieves better performance than simply considering all 
overlapping regions as positives. 
 
Supplementary Figure 5. EnhancerFinder feature weights highlight the contribution 
of different functional genomics data types to enhancer predictions. Each “+” 
represents the contribution made by a single data feature, e.g. H3K4me1 peaks from 
embryonic stem cells, to the classification in EnhancerFinder Step 1 (developmental 
enhancers versus genomic background). Positive weights (red) indicate an association 
with enhancer activity in our analysis and negative weights (blue) suggest a lack of 
enhancer activity. The features plotted here come from a range of likely relevant contexts 
(Relevant Functional Genomics classifier; Supplementary Table 1), and the number of 
data sets present for each feature type is given in parentheses. The black bar gives the 
average weight over all features of each type. In general, the features with high average 
weights, such as H3K3me1, p300, and H3K4me2, are known to be associated with 
enhancers, while those with large negative weights are associated with other types of 
genomic regions. However, no data type has uniformly positive or negative weights in all 
contexts. 
 
Supplementary Figure 6. Heart enhancers are less conserved and closer to the 
nearest transcription start site (TSS) than limb and brain enhancers. Considering 
only limb and brain enhancers that are less evolutionarily conserved and close to a TSS 
improved our ability to identify them, but they are still more difficult to identify than 
heart enhancers. The high GC content of heart enhancers proved essential to the ease of 
predicting them (Supplementary Figure 7). 
 
Supplementary Figure 7. The uniquely high GC content of heart enhancers in 
VISTA enables accurate classification. The VISTA heart enhancers have higher GC 
content (49%) than other types of enhancers and the genomic background (~40%). (A) 
The classification score from a spectrum kernel classifier trained to distinguish heart 
enhancers within VISTA (Step 2) is strongly correlated (Pearson rho=0.95) with the GC 
content of the input region. (B) A classification algorithm based solely on GC content 
(black) performs competitively with the spectrum kernel (AUC of 0.80 vs. 0.82), and 
nearly as well as EnhancerFinder (0.85; Figure 5). 
 
Supplementary Figure 8. Enhancers active in multiple tissues are easier to identify 
than those active in a single tissue. There are 399 enhancers active in a single tissue at 
E11.5 in the VISTA database and 312 active in multiple tissues.  EnhancerFinder is better 
able to distinguish the enhancers active in multiple tissues from the VISTA negatives 
(AUC=0.75) than it is to distinguish single tissue enhancers from the negatives 
(AUC=0.67). This trend also holds across each tissue individually. However, both sets 
are easy to distinguish from the genomic background (AUC=0.96 for both, not shown). 
 
Supplementary Figure 9. Transient transgenic mouse embryos support a novel 
cranial nerve enhancer near ZEB2. Seven transient transgenic mouse embryos showed 
LacZ expression at embryonic day 11.5. Constructs containing a 999 bp region 
(hg19.chr2:145,234,541-145,235,539) including 2xHAR.240 near ZEB2, a minimal 
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promoter, and LacZ were used for human. The orthologous region was used in the chimp 
construct (panTro2.chr2b:148,811,929-148,812,929). Three embryos with constructs 
containing the human version of the region of interest and four embryos containing the 
chimp sequence had staining.  In all embryos, there is consistent expression in the cranial 
nerve.  There does not appear to be a significant difference between human and chimp at 
this time point. 
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AB
DNA Sequence 
Motifs (714)
Functional 
Genomics (643)
Evolutionary 
Conservation 
(770)
472
53 74
113
111
44
76
C
A B

Two Step Prediction Tissue Overlap
Brain
Limb
Heart
56
21
66
24
345117
71
One Step Prediction Tissue Overlap
Brain Limb
Heart
13
21
656
19
23
608
33
VISTA Positive Tissue Overlap
BrainLimb
Heart
4
90 355
5
33
71
4
A
B
C
Heart 
19,051 
Limb 
7,400 
Brain 
11,693 1,279 
604 1,954 
197 
Midbrain development
Negative regulation of 
neuron differentiation
Neuron fate commitment
Primary neural tube 
formation
Cell differentiation in 
spinal cord
Negative regulation of protein 
kinase activity
Negative regulation of 
phosphate metabolic process
Artery morphogenesis
Negative regulation of 
phosphorylation
Negative reulation of 
transferase activity
TGF-beta receptor 
signaling pathway
Regulation of fibroblast 
proliferation
Artery morphogenesis
Gene silencing
Artery development
500 kb hg19
145,200,000 145,300,000 145,400,000 145,500,000 145,600,000 145,700,000 145,800,000 145,900,000 146,000,000 146,100,000 146,200,000 146,300,000 146,400,000 146,500,000
UCSC Genes (RefSeq, UniProt, CCDS, Rfam, tRNAs & Comparative Genomics)
Predicted Enhancers
Human Accelerated Regions
VISTA Enhancers
Regions tested in El-Kasti et al. 2012
E1
ZEB2
chr2:
100 kb hg19
145,150,000 145,200,000 145,250,000 145,300,000 145,350,000 145,400,000
H3K4Me1 Mark (Often Found Near Regulatory Elements) on 7 cell lines from ENCODE
H3K27Ac Mark (Often Found Near Active Regulatory Elements) on 7 cell lines from ENCODE
Digital DNaseI Hypersensitivity Clusters from ENCODE
Transcription Factor ChIP-seq from ENCODE
Placental Mammal Basewise Conservation by PhyloP
UCSC Genes (RefSeq, UniProt, CCDS, Rfam, tRNAs & Comparative Genomics)
Predicted Enhancers
Human Accelerated Regions
VISTA Enhancers
ZEB2
2xHAR.381 2xHAR.240 2xHAR.356
chr2:
VISTA 1802 Novel EnhancerVISTA 407 
